T-cell Leukemia Pipeline: Comprehensive Analysis of 15+ Key Players and 15+ Key Therapies

·5 min read

Out of all T-cell Leukemia pipeline therapies, HBI-8000 is set to capture the maximum patient pool owing to its immunomodulatory function.

Los Angeles, USA, May 05, 2021 (GLOBE NEWSWIRE) -- T-cell Leukemia Pipeline: Comprehensive Analysis of 15+ Key Players and 15+ Key Therapies

Out of all T-cell Leukemia pipeline therapies, HBI-8000 is set to capture the maximum patient pool owing to its immunomodulatory function.

DelveInsight’s T-cell Leukemia Pipeline Insights report provides a holistic view of the pipeline therapies that are under development in pre-clinical as well as clinical stages of development, and growth prospects across the T-cell Leukemia domain.

Some of the key highlights of the T-cell Leukemia Pipeline report:

  • T-cell Leukemia Pipeline report offers a comprehensive analysis of 15+ key players and 15+ key therapies.

  • Out of all the emerging therapies, HBI-8000 is expected to capture the maximum patient pool owing to its immunomodulatory function. This oral agent targets class I histone deacetylase causing cell cycle arrest and tumor cell death as the mechanism underlying its single-agent activity against lymphoma.

  • T-cell Leukemia pipeline comprises ASTX 660 (Otsuka Pharmaceutical) is in phase I/II while Valemetostat and Brentuximab vedotin (Seagen/Takeda) is in Phase II stage of development.

  • HUYA Bioscience appears to have an upper edge as its therapy, HBI-8000 which is in the pre-registration phase.

  • In April 2021, Shorla Pharma announced that the U.S. Food and Drug Administration (FDA) has accepted the filing application of its oncology drug SH-111 which is designed to treat T-cell Leukemia.

Got queries? Want to know more? Request for Sample @ T-cell Leukemia Emerging Therapies and Forecast

The report lays down a complete coverage of the therapeutics by development stage, product type, and route of administration, molecule type, and MOA type for T-cell Leukemia across the complete product development cycle, including all clinical and non-clinical stages.

The T-cell Leukemia pipeline report puts on the table business opportunities, threats, prospective collaborations, strong competitors, growth strategies, and failed as well as discontinued drugs.

T-cell Leukemia Pipeline Drugs

Drug

Company

Clinical Phase

MoA

RoA

Valemetostat

Daiichi Sankyo

Phase II

Histone-lysine N-methyltransferase inhibitors

Oral

BNZ-1

Bioniz

Phase II

Interleukin receptor antagonists

Intravenous

ASTX 660

Otsuka Pharmaceutical

Phase I/II

Inhibitor of apoptosis protein inhibitors;

Oral

Brentuximab vedotin

Seagen /
Takeda

Phase II

Apoptosis stimulants

Intravenous

HBI-8000

HUYA Bioscience

Preregistration

Ras protein inhibitors

Oral

Request for Sample to know more @ T-cell Leukemia Pipeline Analysis, Key Companies and Futuristic Trends

T-cell Leukemia Therapeutic Assessment

The T-cell Leukemia Pipeline report proffers exhaustive insights into active pipeline assets segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Indications of various drugs.

By Product Type

  • Mono

  • Combination

By Stage

  • Discovery

  • Pre-clinical

  • IND

  • Phase I

  • Phase II

  • Phase III

  • Pre-registration

By Molecule Type

  • Small Molecule

  • Gene Therapy

  • Stem Cell Therapy

By Route of Administration

  • Intravenous

  • Inhalation

  • Oral

  • Subcutaneous

By Mechanism of Action

  • Enhancer of zeste homolog 1 and 2 protein inhibitors

  • Histone-lysine N-methyltransferase inhibitors

  • Interleukin 15 receptor antagonists

  • Interleukin 2 receptor antagonists

  • Interleukin 9 receptor antagonists

  • 1 Phosphatidylinositol 3 kinase inhibitors

  • HDAC 1,2,3, and 10 protein inhibitors

  • Mitogen-activated protein kinase inhibitors

By Targets

  • Protease

  • Multiple Kinase

  • Interleukin 15 receptor

  • Interleukin 2 receptor

  • Interleukin 9 receptor

  • Histone-lysine N-methyltransferase

Get in touch with our Business executive for Rich and Deep Market Assessment and Consulting Solutions

Scope of the Report

Coverage: Global
Key Players: Daiichi Sankyo; Bioniz; Otsuka Pharmaceutical; Seagen /Takeda; HUYA Bioscience; iCell Gene Therapeutics; Gracell Biotechnology; Ascentage Pharma Group; Celgene Corporation; Shorla Pharma; AVM Biotechnology; Expression Therapeutics; miRagen Therapeutics, and others.
Key T-cell Leukemia Pipeline Therapies: Valemetostat; BNZ-1; ASTX 660; Brentuximab vedotin; HBI-8000; CD4CAR; CD7 UCAR-T cells; APG-115; Romidepsin; SH-111; Cobomarsen; AVM-0703, and others.

Reach out @ T-cell Leukemia Pipeline: Novel therapies and emerging technologies

Table of Contents

1

Introduction

2

Executive Summary

3

T-cell Leukemia Overview

4

T-cell Leukemia Pipeline Therapeutics

5

T-cell Leukemia Pipeline Therapeutic Assessment

6

T-cell Leukemia – DelveInsight’s Analytical Perspective

7

In-depth Commercial T-cell Leukemia Pipeline Assessment

8

T-cell Leukemia Collaboration Deals

9

Late Stage T-cell Leukemia Pipeline Products (Phase III and Preregistration)

10

Mid-Stage T-cell Leukemia Pipeline Products (Phase II)

11

Pre-clinical and Discovery Stage T-cell Leukemia Pipeline Products

12

Inactive T-cell Leukemia Pipeline Products

13

T-cell Leukemia Key Companies

14

T-cell Leukemia Key Products

15

T-cell Leukemia Unmet Needs

16

T-cell Leukemia Market Drivers and Barriers

17

T-cell Leukemia Future Perspectives and Conclusion

18

T-cell Leukemia Pipeline Analyst Views

20

Appendix

Visit to know more of what’s covered @ T-cell Leukemia Emerging Therapies

Browse through Related Reports

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia
DelveInsight’s “CAR T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL)- Market Insights and Market Forecast- 2030” report.

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Pipeline
DelveInsight’s, “CAR T-Cell Therapy for Acute Lymphoblastic Leukemia - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline landscape.

Adult T Cell Leukemia Lymphoma Market
DelveInsight's "Adult T-Cell Leukemia-Lymphoma - Market Insights, Epidemiology, and Market Forecast-2030" report.

Acute Myeloid Leukemia Market
DelveInsight's "Acute Myeloid Leukemia (AML) Market Insights, Epidemiology, and Market Forecast-2030" report.

B-Cell Chronic Lymphocytic Leukemia Market
DelveInsight's "B-Cell Chronic Lymphocytic Leukemia - Market Insights, Epidemiology, and Market Forecast-2030" report.

Hairy Cell Leukemia Market Insight Epidemiology and Market Forecast
DelveInsight's 'Hairy Cell Leukemia (HCL)- Market Insights, Epidemiology and Market Forecast-2028' report.

Bowens Disease Market
DelveInsight's "Bowen's Disease - Market Insights, Epidemiology, and Market Forecast-2030" report.

Buergers Disease Market
DelveInsight's "Buerger’s Disease - Market Insights, Epidemiology, and Market Forecast-2030" report.

Brucellosis Market
DelveInsight's "Brucellosis - Market Insights, Epidemiology, and Market Forecast-2030" report.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News

CONTACT: Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com